Having trouble accessing articles? Reset your cache.

Intrepida: Tackling the innate immune system to treat cancer

Intrepida Bio is developing first-in-class mAbs against BAG3 to modulate the TME

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer.

The company hopes the target will be a differentiator in the already crowded immuno-oncology space.

Sofinnova Investments and Canaan Partners co-led the financing round with participation from Indaco Venture Partners and Vertis SGR.

Intrepida Bio Inc. is founded on work

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE